| Since January 2002, we have been co-promoters for four main products in main therapeutic areas, namely |
| Anti diabetics |
| Antibiotics |
| Vaso-therapeutics |
| Peptic ulcers |
|
| Key facts: |
|
| During four consecutive years we have managed to achieve over 90% from target. |
|
| When we acquired the account in 2002, and according to the IMS, TARIVID ranked 7th in its class. Today TARIVID is the second runner up. |
|
| When we acquired the account in 2002, Trental annual sales amounted to 1,000,000 units. Today its annual turnover reached 1,360,000 units which represent 36% cumulative growth. |
|
| Performance measurement set, policies and procedures |
|
|
|
.jpg){kind=small}
